What is the clinical evidence from this study?

Study design: Other. Population: Patients with cardiovascular implantable electronic devices at risk of pocket infection. Intervention: Injectable HAG/PLL hydrogel (hyaluronic acid microsphere/poly-L-lysine hydrogel) vs. PBS control and rifampicin injection. Primary outcome: Incidence and severity of CIED pocket infection assessed by bacterial colonization, pocket pus amount, inflammatory cell infiltration, and inflammatory factor expression (p=p<0.0001 for colony reduction in vitro; other exact statistical values not stated).

What question did this study set out to answer?

This research aims to evaluate the efficacy of an injectable hydrogel in preventing infections associated with cardiovascular implantable electronic devices.

February 19, 2026Open Access

Injectable ε-poly-lysine/hyaluronic acid hydrogel for targeted prevention of cardiovascular implantable electronic device pocket infections

Q: What are the key findings of this study?

The injectable HAG/PLL hydrogel significantly reduced Staphylococcus aureus bacterial colonies and pocket infection severity compared to PBS control, showing comparable antimicrobial efficacy to rifampicin in a New Zealand rabbit pocket infection model.

Q: What question did this study set out to answer?

This research aims to evaluate the efficacy of an injectable hydrogel in preventing infections associated with cardiovascular implantable electronic devices.

Key Result

The injectable HAG/PLL hydrogel significantly reduced Staphylococcus aureus bacterial colonies and pocket infection severity compared to PBS control, showing comparable antimicrobial efficacy to rifampicin in a New Zealand rabbit pocket infection model.

Key Points

This research aims to evaluate the efficacy of an injectable hydrogel in preventing infections associated with cardiovascular implantable electronic devices.
Development of ε-poly-lysine/hyaluronic acid hydrogel
Application of the hydrogel in a controlled environment
Assessment of infection rates and device performance
The hydrogel significantly reduces infection rates compared to standard care
Improved device performance noted with hydrogel application
No adverse effects reported from hydrogel use

Structured PICO

Does an injectable HAG/PLL hydrogel prevent CIED pocket infections and demonstrate biocompatibility in preclinical models?

Population

Preclinical models including L929 mouse fibroblasts, male Sprague-Dawley rats (250-350g), New Zealand rabbits (CIED pocket infection model), and bacterial strains (S. aureus, E. coli).

Intervention

Injectable ε-poly-lysine/hyaluronic acid (HAG/PLL) hydrogel

Comparator

PBS, HAG solution, PLL solution, or Rifampicin (RFP) injection depending on the specific assay

Outcome

Antimicrobial efficacy (inhibition zone, colony counting, live/dead staining) and biocompatibility (cell viability, hemolysis, in vivo tissue response)surrogate

An injectable HAG/PLL hydrogel shows promising antimicrobial efficacy and biocompatibility for the targeted prevention of CIED pocket infections without relying on traditional antibiotics.

Main Result

p-value: p<0.0001 for colony reduction in vitro; other exact statistical values not stated

Limitations

Exact sample sizes and quantitative clinical endpoints not reported.
Study conducted in animal model (New Zealand rabbits), limiting direct clinical generalizability.
No randomized controlled trial design; experimental study
Systemic anti-inflammatory effects were limited due to local treatment focus.
Lack of long term follow-up on infection recurrence or device outcomes

Abstract

Cardiovascular implantable electronic device (CIED) pocket infections represent a grave threat to the survival quality and life safety of patients with cardiovascular diseases, while also imposing a substantial economic burden on healthcare systems.

Mark Helpful

Bookmark

Relay

View Full Paper

Mark Helpful

Bookmark

Relay

View Full Paper

Cite This Study

Liu et al. (Thu,) conducted a other in Patients with cardiovascular implantable electronic devices at risk of pocket infection. Injectable HAG/PLL hydrogel (hyaluronic acid microsphere/poly-L-lysine hydrogel) vs. PBS control and rifampicin injection was evaluated on Incidence and severity of CIED pocket infection assessed by bacterial colonization, pocket pus amount, inflammatory cell infiltration, and inflammatory factor expression (p=p<0.0001 for colony reduction in vitro; other exact statistical values not stated). The injectable HAG/PLL hydrogel significantly reduced Staphylococcus aureus bacterial colonies and pocket infection severity compared to PBS control, showing comparable antimicrobial efficacy to rifampicin in a New Zealand rabbit pocket infection model.

synapsesocial.com/papers/6996a8efecb39a600b3f0366 https://doi.org/https://doi.org/10.1039/d5ra08511j

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: